Lowell R&D Tax Credit Benefits for Corporations

R&D Tax Credits for Lowell, Massachusetts Businesses

Lowell, Massachusetts, thrives in industries such as healthcare, education, technology, and retail. Top companies in the city include Lowell General Hospital, a major healthcare provider; the University of Massachusetts Lowell, a key educational institution; Raytheon, a prominent technology company; Walmart, a global retail giant; and Amazon, a global logistics and e-commerce company. The R&D Tax Credit can benefit these industries by reducing tax liabilities, fostering innovation, and improving business performance. By leveraging the R&D Tax Credit, companies can reinvest savings into advanced research boosting Lowell’s economic growth.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6 Liberty Square, Boston, Massachusetts is less than 30 miles away from Lowell and provides R&D tax credit consulting and advisory services to Lowell and the surrounding areas such as: Boston, Worcester, Cambridge, Manchester and Nashua.

If you have any questions or need further assistance, please call or email our local Massachusetts Partner on (857) 347-5915.
Feel free to book a quick teleconference with one of our Massachusetts R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Lowell, Massachusetts Patent of the Year – 2024/2025

Alcyone Therapeutics Inc. has been awarded the 2024/2025 Patent of the Year for advancing targeted drug delivery to the brain and spine. Their invention, detailed in U.S. Patent No. 11904128, titled “Fluid delivery system”, introduces a catheter-based technology that improves how medicine is delivered into the central nervous system.

This system enhances precision and safety when delivering therapies directly into the cerebrospinal fluid. The catheter includes flow control features and structural improvements that reduce the risk of leaks or improper dosing. It also supports long-term use, allowing consistent delivery of medication over extended periods without repeated surgeries or interventions.

Alcyone’s innovation is designed to meet the needs of patients with neurological and rare diseases. It enables more effective use of biologics, gene therapies, and other advanced treatments that require precise placement within the spinal or brain region. The controlled flow system ensures medicine reaches its target without causing pressure spikes or tissue damage.

In real-world terms, this means better outcomes and fewer complications for patients undergoing complex treatments. It also reduces burdens on caregivers and hospitals by streamlining administration and monitoring. Alcyone’s fluid delivery system represents a major step forward in neurotherapeutics, opening the door to safer, more effective care for some of the most challenging conditions in medicine.